ILYA PHARMA is a clinical stage biopharmaceutical company developing next-generation biologics to treat skin and mucosa wounds to validate clinical proof-of-concept. The innovative drug candidates are based on internationally cutting-edge science in immune-physiology and technical microbiology. Ilya has received numerous awards and recognition in the field of advanced therapies, and has so far raised €10 M in private funding and €7 M in grant funding. The company has expanded its team over the last 24 months and is today semi-virtual engaging approximately 40 experts/16 FTEs in the core group and 30 subcontractors and a large group of advisors chaperoning the developments.
Content by this speaker
Further Activities to have a look at